Incidence rates of adverse events of interest in patients with rheumatoid arthritis treated with adalimumab (N=15 152; 24,810.4 PYs)
| Adverse events | E (E/100 PYs) |
|---|---|
| Serious infections | 1154 (4.7) |
| Active tuberculosis (TB) | 63 (0.3) |
| Opportunistic | 14 (<0.1) |
| Zoster | 19 (<0.1) |
| Non-serious infections | |
| Opportunistic infections, excluding oral candidiasis, herpes zoster and TB | 26 (0.1) |
| Herpes zoster | 424 (1.7) |
| Reactivation of hepatitis B* | 3 (<0.1) |
*Two patients experienced three events of hepatitis B reactivation: chronic hepatitis B, hepatitis B and viral hepatitis carrier.
E, number of events; E/100 PYs, events per 100 patient-years.